AbCellera Biologics Inc. has announced that it has received a No Objection Letter from Health Canada, authorizing the company to initiate a Phase 1 clinical trial for ABCL635. This investigational antibody antagonist targets the neurokinin 3 receptor (NK3R) and is being developed as a non-hormonal treatment for moderate-to-severe vasomotor symptoms (VMS) associated with menopause, commonly known as hot flashes. The Phase 1 trial, scheduled to begin in the third quarter of 2025, will assess the safety, pharmacokinetics, and pharmacodynamics of ABCL635 in healthy participants and postmenopausal women experiencing these symptoms. AbCellera aims to explore ABCL635 as a potential long-acting treatment option for this significant health issue affecting millions of women.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.